ReviewFrontiers in pharmacology2026
GPR55 and PINK1 as emerging therapeutic targets in Glioma: insights into their modulation by phytochemicals and plant extracts.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expression of certain genes and proteins in brain tumors, particularly gliomas, presents potential therapeutic targets and biomarkers. One of such genes encodes the protein PINK1 (PTEN-induced Kinase 1), which has been primarily studied due to its mutations being linked to Parkinson's disease (PD). Additionally, epidemiological studies have observed a reduced risk of developing certain types of cancer in patients with neurodegenerative diseases and vice versa. The GPR55 receptor (G protein-coupled receptor 55) exhibits pro-oncogenic properties, and its expression correlates with tumor aggressiveness and the activation of the MAPK/ERK signaling pathway. This review would aim to provide an overview of the current understanding of the relationship between PINK1 and GPR55 proteins in glioma pathophysiology and explore the potential use of plant extracts as a therapeutic alternative to regulate their expression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.